Bedel Financial Consulting Inc. Has $395,000 Position in Amgen Inc. (NASDAQ:AMGN)

Bedel Financial Consulting Inc. boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 4.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,517 shares of the medical research company’s stock after acquiring an additional 66 shares during the quarter. Bedel Financial Consulting Inc.’s holdings in Amgen were worth $395,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Gryphon Financial Partners LLC raised its stake in Amgen by 5.8% during the fourth quarter. Gryphon Financial Partners LLC now owns 4,475 shares of the medical research company’s stock worth $1,166,000 after acquiring an additional 245 shares in the last quarter. Silver Coast Investments LLC increased its stake in shares of Amgen by 5.4% in the fourth quarter. Silver Coast Investments LLC now owns 935 shares of the medical research company’s stock valued at $244,000 after buying an additional 48 shares in the last quarter. Auxano Advisors LLC increased its stake in shares of Amgen by 2.7% in the fourth quarter. Auxano Advisors LLC now owns 2,578 shares of the medical research company’s stock valued at $672,000 after buying an additional 68 shares in the last quarter. Woodley Farra Manion Portfolio Management Inc. increased its stake in shares of Amgen by 2.7% in the fourth quarter. Woodley Farra Manion Portfolio Management Inc. now owns 14,126 shares of the medical research company’s stock valued at $3,682,000 after buying an additional 371 shares in the last quarter. Finally, Fidelis Capital Partners LLC increased its stake in shares of Amgen by 3.6% in the fourth quarter. Fidelis Capital Partners LLC now owns 4,609 shares of the medical research company’s stock valued at $1,331,000 after buying an additional 160 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently weighed in on AMGN. Leerink Partners lowered their target price on Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Piper Sandler lifted their price objective on Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. William Blair reiterated an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Citigroup restated a “neutral” rating on shares of Amgen in a research report on Wednesday, February 5th. Finally, Redburn Partners decreased their target price on Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $314.09.

Insiders Place Their Bets

In other news, EVP Murdo Gordon sold 8,771 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the sale, the executive vice president now directly owns 44,186 shares of the company’s stock, valued at approximately $13,025,590.94. This represents a 16.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock worth $20,644,335 in the last 90 days. Company insiders own 0.69% of the company’s stock.

Amgen Stock Up 0.9 %

AMGN opened at $310.78 on Tuesday. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The stock’s fifty day simple moving average is $281.80 and its 200 day simple moving average is $299.73. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The stock has a market cap of $166.95 billion, a PE ratio of 41.16, a price-to-earnings-growth ratio of 2.63 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This is a boost from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 annualized dividend and a yield of 3.06%. Amgen’s dividend payout ratio (DPR) is presently 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.